Kornimate/medical-research-clean huggingface dataset:
coughing at time of cervical biopsy

Conditions: Cervical Cancer; Cervical Dysplasia; Colposcopy; Pain Sensation; Cervical Biopsy

Summary: to investigate the effect of coughing as an intervention to reduce pain in colposcopy guided biopsy.

colposcopy is a frequently practiced examination and colposcopy guided biopsy causes pain. a few trials investigated whether medical interventions such as the application of lidocaine led to reduced pain perception with inconsistent results. only one trial compared coughing versus no coughing at the moment of biopsy. although the results of this study did not lead to a significant difference between the two study arms, coughing seems to positively affect pain perception. since the patients are, in the best case, their own controls when it comes to subjective parameters such as pain perception, we prefer a cross-over rather than a parallel group design. based on the descriptive variables for pain during biopsy with and without cough determined in the pilot study, a case estimate for a prospective randomized cross-over study will be carried out. since two biopsies are usually taken from the cervix in daily practice, the now planned pilot study in a cross-over design envisages the following two study arms: 1. group i: patients cough during the first biopsy, they do not cough during the second biopsy 2. group ii: patients cough during the second biopsy, they do not cough during the first biopsy the primary outcome measure is the difference in the patients' perception of pain during the first and second biopsy on the cervix (ectocervix), measured using an 11-part numerical analogue scale (11-item nas).

Eligibility criteria:
inclusion criteria: * completed 18 years of age * written informed consent * first colposcopy * clinically indicated colposcopy in case of an abnormal pap smear or screening result and/or clinical abnormalities on the cervix uteri * necessity to take exactly two biopsies exclusion criteria: * performing only one biopsy or more than two biopsies * performing an endocervical curettage (biopsy on the endocervix) * vaginal bleeding at the time of examination * inadequate colposcopy * cervix uteri cannot be fully visualized * pregnancy * patients with insufficient german language skills * known anxiety disorders or depressive disorders * treatments already carried out on the cervix uteri * patients with a chronic or acute illness that influences the perception of pain or lead to permanent pain due to the disease itself * psychosomatic illnesses * chronic use of pain medications or psychotropic medications or other medications that may have an influence on the sensation of pain

Keywords: cervical cancer cervical dysplasia cervical biopsy pain coughing distraction
psychological intervention for caregivers of patients with malignant gliomas

Conditions: Malignant Glioma

Summary: this research study is evaluating a psychological intervention for caregivers of loved ones with malignant gliomas.

caregivers of loved ones with malignant gliomas frequently experience a physical and psychological burden caring for their loved ones. the purpose of this study is to find out whether a psychological intervention can help caregivers learn effective coping methods during their loved one's treatment and make the experience of being a caregiver more manageable. the psychological intervention will take place in a series of six sessions. a trained social worker or psychologist will meet with the participant or talk with the participant over the telephone or by video conference for 45 minutes at a time to discuss the caregiver experience while developing effective skills to support the loved one as well as the participant over the course of the loved one's illness. upon the completion of the sessions, the investigators will have a short (30-minute) exit interview to obtain the participant's feedback on the intervention. the investigators will use the feedback to improve the intervention before further testing its effectiveness in future research studies. the investigators will also ask the participant to complete questionnaires before and after their participation in the intervention to help the investigators understand the participant's coping skills, caregiving burden, mood, and understanding about the loved one's illness.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * identified by a patient with a malignant glioma (who grade iii or iv glioma) as the patient's primary caregiver * the patient is receiving care at the mgh cancer center * the patient was diagnosed with a malignant glioma within the past 6 months * able to speak and read in english * generalized anxiety disorder 7-item (gad-7) score ≥5 * participants may or may not be pregnant. exclusion criteria: * deemed inappropriate for the study by the patient's clinician or the study pi

Keywords: malignant gliomas
active nutrition program on weight loss

Conditions: Weight Loss

Summary: the study will evaluate the impact of the active nutrition 60-day program from usana on weight loss and related measures, such as body composition, physical appearance/body shape, perceived wellness, and biochemical markers of health (e.g., blood lipids, glucose, insulin).

to date, no controlled study exists to evaluate the impact of the active nutrition program from usana on weight loss and related measures, such as body composition, physical appearance/body shape, perceived wellness, and biochemical markers of health (e.g., blood lipids, glucose, insulin). therefore, the purpose of the proposed study is to evaluate the active nutrition weight loss program on body weight and related variables in a sample of overweight and obese men and women. subjects in the active nutrition group will be compared to a control group of men and women following their standard diet, for a period of 60 days.

Eligibility criteria:
inclusion criteria: * body mass index 28-39.9 kilograms per square meter * weigh less than 500 lbs * able to fast overnight (greater than 10 hours) exclusion criteria: * tobacco user * diagnosed with type 1 or 2 diabetes * diagnosed with liver disease * adversity to fiber or protein supplements * allergic to any of the ingredients * taking a weight loss dietary supplement or adhering to a weight loss plan for the month prior to or during the study * consumption of alcohol within 24 hours of study visit * consumption of caffeine within 24 hours of study visit * strenuous exercise within 24 hours of study visit * self-reported active infection or illness * pregnant or lactating

Keywords: active nutrition
randomized clinical trial for primary molar pulpotomy, biodentine vs formocresol-zoe

Conditions: Deep Dental Caries

Summary: this is a rct that will compare the clinical and radiographic success of pulpotomies on primary molars between the traditional technique (formocresol/zoe) and the new technique with biodentine. 180 pulpotomies (90 in each group) will be followed for a period of 12 months.


Eligibility criteria:
inclusion criteria: * asa i and ii * less than 1/3 of physiologic root resorption * asymptomatic tooth (with no history of symptoms) * no clinical or radiological sign of pathology * vital tooth, with carious pulpal exposure * hemostasis must be obtained simply with pressure in less than 5 min * teeth restored with stainless steel crowns exclusion criteria: * more than 10 y.o. * symptomatic tooth (presently or history of symptoms) * previous pulpal treatment on the tooth * necrotic pulp * hyperemic pulp * inadequate operative technique, defective restauration * non diagnostic x-ray (pre or post treatment)
proof of concept (poc) study of the soliton rapid acoustic (rap) for the treatment of cellulite

Conditions: Cellulite

Summary: feasibility study is to evaluate the safety, tolerability and efficacy of soliton's rapid acoustic pulse (rap) device for the treatment of cellulite

to assess the safety and tolerability of soliton's rap nov heavy for the treatment of cellulite. to assess the efficacy of soliton's rap nov heavy device for the temporary improvement in appearance of cellulite in terms of mean change in cellulite severity score (css).

Eligibility criteria:
inclusion criteria: * female ages 18-65 years * participant seeking treatment of cellulite in the upper lateral thigh areas * participant presenting with cellulite grade i or ii on both thighs as graded using the nurnberger-muller scale classification (appendix a) * participant has stable weight. body mass index (b.m.i.) is ≤ 30 * participant will not have any other cellulite treatments for 12 months before and throughout the 3-month follow-up * participant is willing to participate in study and adhere to follow-up schedule * participant is able to read and comprehend english * participant has completed informed consent form exclusion criteria: * participant is pregnant or planning to become pregnant during the duration of the study * participant has a bmi \> 30 * greater than 10% increase or decrease in body weight within past 6 months * cellulite treatment on the thighs or buttocks in the last 12 months (topical or non-invasive procedure) * metal or plastic implants in the area of the treatment (vascular stent, or implants in the hips, knees, etc.) * active electronic implants such as pacemakers, defibrillators, cochlear implants, nerve/brain stimulators, drug pump, etc. * prior liposuction in the thighs or buttocks or any other invasive procedure to limit cellulite. * medical disorder that would hinder the wound healing or immune response (no blood disorder, diabetes, inflammatory disease, etc.)
early diagnosis of malignant transformation of pigmentary skin lesions

Conditions: Malignant Melanoma; Pigmented Nevi; Skin Neoplasm

Summary: malignant melanoma is a deadly skin cancer that can be cured if diagnosed early. to date atypical pigmented skin lesions are diagnosed by appearance alone and many moles and lesions are excised unnecessarily and on the other hand malignant lesions are missed and diagnosed too late. in this study a protein conjugated to a florescent dye is spread on a suspicious pigmented lesion, the hypothesis is that this protein binds to malignant cells only and thus with a special camera that picks up the dye we can find pigmented lesions with early malignant transformation.


Eligibility criteria:
inclusion criteria: * pigmented lesion indicated for surgical excision * over 18 years of age exclusion criteria: * pregnancy
impact of the lab-score on antibiotic prescription rate in children with fever without source

Conditions: Fever Without Source

Summary: detecting serious bacterial infections (sbi) in children presenting to the pediatric emergency department (ped) with fever without source (fws) is a frequent diagnostic challenge. the recently described lab-score, based on the combined determination of procalcitonin, c-reactive protein (crp) and urine dipstick results, has been shown an accurate tool for sbi prediction on retrospective cohorts. the investigators aimed to assess the usefulness of the lab-score in safely decreasing unnecessary antibiotic prescriptions in children with fws, and to prospectively determine the diagnostic characteristics of the lab-score compared to other classically used sbi biomarkers (white blood cell (wbc) count, band count and crp).


Eligibility criteria:
inclusion criteria: * children aged 7 days to 3 years old * fever without source ≥ 100.4°f (≥ 38.0°c) exclusion criteria: * antibiotics received in the previous 48 hours * underlying congenital or acquired immunodeficiency syndrome * fever for more than 7 days at presentation

Keywords: fever without source antibiotic prescription serious bacterial infection
anti-inflammatory effect of serum of osteoarthritis patients after administration of the oléogrape®seed, an extract of grape and olive

Conditions: Osteoarthritis

Summary: osteoarthritis is a degenerative disease that affects a growing proportion of the population. there is currently no treatment to halt this process. the aim of the research is in particular to find treatments targeting the molecular origins of osteoarthritis focusing especially on the inflammatory component of the disease. that is why research is looking to the development of preventive treatments like nutraceuticals. this project aims to determine the anti-inflammatory properties of sera of patients who received supplementation of their diet with an extract of grape and olive: the oléogrape®seed. sera and synovial fluid will be collected during visits for hyaluronic acid injections in oa patients. these sera will be tested in vitro in a model of inflamed chondrocytes.


Eligibility criteria:
inclusion criteria: * 50 years old and over * patients with knee osteoarthritis (acr criteria) * patients requiring injection of hyaluronic acid (no corticosteroid associated) * radiological stage of knee osteoarthritis 1, 2 or 3 (kellgren-lawrence) * informed consent form signed exclusion criteria: * younger than 50 years * protected adult * pregnant woman * radiological stage 4 osteoarthritis (kellgren-lawrence) * knee osteoarthritis secondary to arthritis * taking a long term treatment of osteoarthritis (piasclédine®, diacéréine®, glucosamine, chondroitin) * inflammatory pathology other than osteoarthritis * taking anti-inflammatory medications * refusal to participate in the study * use of food supplements with anti-inflammatory properties * arthroscopy less than 6 months * corticosteroid injection \<3 months * inr\> 4 or tca\> 2 (anticoagulants) * being allergic to lactose
nifedipine compared to atosiban for treating preterm labor

Conditions: Labor, Premature

Summary: the purpose of this study is to investigate the efficacy and the safety of nifedipine compared to atosiban for treating preterm labor.


Eligibility criteria:
inclusion criteria: 1. gestational age between 24 to 34 weeks which had been documented by a definite lmp and sonography up to 20 weeks. 2. all women fulfilled the criteria of preterm labor. the diagnosis of preterm labor required the presence of 4 uterine contractions or more over 30 minutes, each lasting at least 30 seconds, and documented cervical change. the cervical criteria were met when either of the following was present: 1. nulliparous women: a single cervical examination demonstrating dilatation of 0 cm to 4 cm and effacement of at least 50% 2. multiparous women: a single cervical examination demonstrating dilatation of 1 cm to 4 cm and effacement of at least 50%. 3. provision of written informed consent exclusion criteria: 1. chorioamnionitis 2. preterm rupture of membranes 3. vaginal bleeding 4. major fetal malformations 5. severe hypertensive disorders 6. intrauterine growth restriction (\< 5th percentile). 7. non-reassuring fetal heart rate 8. maternal contraindications 1. chronic hypertension 2. systolic blood pressure \< 90 mmhg 3. cardiovascular disease 4. elevated hepatic enzymes 9. congenital or acquired uterine malformation

Keywords: preterm labor atosiban nifedipine
improving quality of osteoporosis care through patient storytelling

Conditions: Osteoporosis

Summary: the purpose of this exploratory study is to test novel, mailed, low-cost, direct-to-patient intervention materials (i.e., a personalized letter and osteoporosis information pamphlet) designed to increase rates of dual energy x-ray absorptiometry (dxa) utilization and improve osteoporosis quality of care.

while the occurrence of a fragility fracture (e.g. hip fracture) is indicative of low bmd and a clinical diagnosis of osteoporosis made, osteoporosis can be identified in asymptomatic patients using dual energy x-ray absorptiometry (dxa). united states (u.s.) guidelines recommend screening bone density tests using central dxa in all women 65 years or older. however, fewer than one-third of eligible u.s. women age 65 and older undergo dxa testing. the main barrier to achieving greater rates of osteoporosis screening is identifying a systematic, effective, and generalizable way for healthcare providers and patients to schedule dxa results. given that national guidelines recommend dxa screening for all older women, the reasons a majority of women do not receive dxa testing are likely multifactorial. patients and their health care providers may be unaware of preventative screening recommendations and the reasons for these recommendations. screening tests that are required relatively infrequently (i.e. less than once a year) may be difficult for patients and physicians to remember if there are few triggers (e.g. seasonality as a trigger to motivate influenza vaccination). additionally, primary care providers (pcps) are responsible for managing a large number of comorbidities and acute care needs and may be unable to stay current with all preventative care needs during increasingly short clinic visits.

Eligibility criteria:
inclusion criteria: * female * age 65 or older * at least one visit with a primary care physician in the previous 12 months exclusion criteria: * dxa scan in the previous 5 years
a clinical study to compare two revascularization protocols to treat non-vital teeth with incomplete root formation

Conditions: Dental Pulp Necrosis; Disorder of Tooth Development

Summary: both methods tested in this study disinfect the non-vital root canals and induce blood clot formation inside the root canal. one method places calcium hydroxide inside the root canal after disinfection and the blood clot is induced four weeks later. the other method performs disinfection and induction of blood clot in one appointment. the investigators hypothesize that both methods will obtain the same success rate in eliminating infection, increase in root length and canal walls thickness.

collagen is placed on top of the blood clot, followed by white mta. glass ionomer is used to seal the access to the canal, which will be replaced by a permanent restoration 3 months later.

Eligibility criteria:
inclusion criteria: * healthy or having a mild systemic disease (asa physical status 1 or 2), with no contraindications to the treatment. * cooperative. * clinical diagnosis of pulp necrosis based on cold test, electric pulp test as well as an identified cause of pulp necrosis such as caries, deep restorations, dental anomalies, history of trauma, associated with radiographic and/or clinic signs of periapical lesion. * open apex with a diameter of at least 1mm. for teeth with more than one apical foramen, at least one foramen needs to be 1mm wide. * tooth is restorable and periodontally stable. exclusion criteria: * pregnancy. * evidence of pathological external or internal root resorption, root fracture or ankylosis.

Keywords: immature teeth calcium hydroxide blood clot revascularization revitalization
cancer detection in pancreatic cysts

Conditions: Pancreatic Cyst; Pancreatic Pseudocyst; Pancreatic Neoplasm

Summary: the purpose of this study is to assist with early and accurate diagnosis of cancer in pancreatic cysts based on the analysis of dna obtained by endoscopic ultrasound guided fine needle aspiration

the study of pancreatic diseases is hindered by the organ's deep seated location and especially lack of symptoms during the early stages of disease development and progression e.g. pancreatic cancer. this is particularly true of pancreatic cysts, the variety and the malignant potential of which encompass a broad spectrum. the radiological features distinguishing a benign from a pre-malignant to a frankly malignant cyst in the pancreas are frequently underwhelming and have lead to the clinical practice of sampling all but the most obvious. the yield of the aspirate in turn is frequently not of a quality upon which a clinical decision can be based. most would agree that the best approach for management of pancreatic cystic neoplasm lies in early diagnosis, ideally at a precancerous stage. the effectiveness and applicability of this study is the based on the ability of the cyst dna analysis to stratify the patients at risk of developing pancreatic cancer based on the extent of accumulated mutational damage.

Eligibility criteria:
inclusion criteria: * previously scheduled for endoscopic ultrasound for evaluation of pancreatic cyst exclusion criteria: * any condition that would preclude safe performance of eus/fna

Keywords: pancreatic cyst panda study
an open label trial of duloxetine in the treatment of irritable bowel syndrome and comorbid generalized anxiety disorder

Conditions: Irritable Bowel Syndrome; Generalized Anxiety Disorder

Summary: the investigators propose to evaluate the effectiveness of duloxetine in treating subjects with both irritable bowel syndrome (ibs) and generalized anxiety disorder (gad). the investigators hypothesize that duloxetine as a single therapeutic agent will effectively target pain and other core symptoms of ibs as well as gad in this patient population with both conditions.

generalized anxiety disorder (gad) is commonly associated with irritable bowel syndrome(ibs). the etiology of ibs remains unknown and it is often refractory to treatment. duloxetine has demonstrated efficacy in the treatment of gad as well as other pain disorders including fibromyalgia and diabetic neuropathy. we plan to study 30 subjects with diagnoses of ibs and gad between the ages of 18 and 65 years. there will be a single-blind placebo-run-in for the first 2 weeks, followed by open-label duloxetine for 12 weeks flexibly titrated to 120 mg/day. subjects will be informed that they will receive placebo for 2 weeks during the trial. all study visits will be at allegheny general hospital department of psychiatry. the study consists of a total of nine office visits.

Eligibility criteria:
inclusion criteria: * 18-65 years of age * active ibs diagnosis by a gastroenterologist * generalized anxiety disorder diagnosed by dsm-iv tr criteria and the mini international neuropsychiatric interview for the dsm-iv (mini) * no changes in any non study medication once starting the study exclusion criteria: * current diagnoses of major depressive disorder, panic disorder, social phobia, post traumatic stress disorder, obsessive compulsive disorders, eating disorders, somatoform disorders, drug or alcohol abuse or dependence, or severe personality disorder * lifetime history of any bipolar disorder or psychotic disorder * concurrent gi disorders falling outside of rome iii functional gi disorders * pregnant women or sexually active female subjects not using medically acceptable method of contraception * current suicidal ideation * unstable medical condition

Keywords: ibs irritable bowel syndrome gad generalized anxiety disorder
food-effect bioavailability of gemigliptin and dapagliflozin 50/10 mg

Conditions: Healthy Volunteers

Summary: a randomized, open-label, single-dose, two-way crossover study to investigate food-effect bioavailability of gemigliptin and dapagliflozin 50/10 mg fixed dose combination film-coated tablet under fed and fasting conditions in healthy volunteers

\[objectives\] * primary: to investigate the food-effect bioavailability of absorption of gemigliptin and dapagliflozin 50/10 mg fixed dose combination film-coated tablet in healthy subjects under fed and fasting conditions * secondary: to evaluate safety of investigational product under fed and fasting conditions

Eligibility criteria:
inclusion criteria: * male and female, healthy volunteers aged 18-55 years, body mass index between 18.0 to 30.0 kg/m2. all of them should be able to complete the clinical study including the follow-up and capable of providing written informed consent. exclusion criteria: * history serious hypersensitivity reactions * history or evidence of clinically significant renal, hepatic, gastrointestinal * have high risk for coronavirus infection based on risk assessment questionnaire or diagnosed as confirmed case of covid-19 * history about administration of first dose or second dose of covid-19 vaccine within 30 days prior to check-in in each period * history or evidence of family diabetes * history or evidence of type 1 diabetes mellitus, diabetic ketoacidosis, diabetic pre-coma * etc.